Ewings sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results provide the proof-of-concept for combining BET inhibitors with agents targeting the IGF1R pathway for treating advanced Ewing sarcoma.
|
30926641 |
2019 |
Ewings sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TAE226, a dual inhibitor of focal adhesion kinase and insulin-like growth factor-I receptor, is effective for Ewing sarcoma.
|
31692287 |
2019 |
Ewings sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The EWS-FLI1/EGR1/IGF1R cascade combined with the previously confirmed pathways can form a speculative circuit, implicating positive feedback for tumourigenesis in ES.
|
31466866 |
2019 |
Ewings sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, these results suggest that IGF1R inhibitors activation is an escape mechanism to CDK4/6 inhibitors in Ewing sarcoma and that dual targeting of CDK4/6 inhibitors and IGF1R inhibitors provides a candidate synergistic combination for clinical application in this disease.
|
30397176 |
2019 |
Ewings sarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
After the formal demonstration of a direct association between IGF2BP3 and <i>IGF1R</i> mRNA using ribo-immunoprecipitation assay, we performed <i>in vitro</i> studies using A673 and TC-71 ES cell lines to demonstrate that IGF2BP3 loss promotes the downregulation of IGF1R and a decreased biological response to IGF1, represented by reduced migration and cell growth.
|
29731738 |
2018 |
Ewings sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our previous study showed that cyclin-dependent kinase 4/6 (CDK4/6) and insulin-like growth factor-1 receptor (IGF-1R) inhibitors were effective on the Ewing's sarcoma PDOX, but not doxorubicin, similar to the patient's resistance to doxorubicin.
|
29262551 |
2017 |
Ewings sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Both tumor architecture and shear force have profound effects on Ewing sarcoma (ES) cell behavior and are known to elicit ligand-mediated activation of the insulin-like growth factor-1 receptor (IGF-1R), thereby mediating resistance of ES cells to IGF-1R inhibitors.
|
27923328 |
2017 |
Ewings sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to determine efficacy of cyclin-dependent kinase 4/6 (CDK4/6) and insulin-like growth factor-1 receptor (IGF-1R) inhibitors on the Ewing's sarcoma PDOX.
|
27286459 |
2016 |
Ewings sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Repression of autocrine IGF1 by BET inhibitors led to significant inhibition of the IGF1R/AKT pathway critical to Ewing sarcoma cell proliferation and survival.
|
27259270 |
2016 |
Ewings sarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we report that IGF1R (15/15) and ROR1 (11/15) were highly expressed in sarcoma cell lines including Ewing sarcoma, osteosarcoma, alveolar or embryonal rhabdomyosarcoma, and fibrosarcoma.
|
26173023 |
2015 |
Ewings sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of IGF1R either by the specific AVE1642 human antibody or by the dual IGF1R/insulin receptor inhibitor OSI-906 (Linsitinib) greatly potentiate the efficacy of trabectedin in the 13 EWS cell lines here considered as well as in TC-71 and 6647 xenografts.
|
25609059 |
2015 |
Ewings sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, despite encouraging in vitro and in vivo results, apart from intriguing results of Insulin-like Growth Factor-1 Receptor (IGF-1R) antibodies in ES, clinical studies are limited or disappointing.
|
24582852 |
2014 |
Ewings sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
β-Arrestin-biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing's sarcoma.
|
23188799 |
2012 |
Ewings sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IGF-I receptor (IGF-IR) has emerged as a good therapeutic site for ES patients.
|
14710346 |
2004 |
Ewings sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate that inhibiting IGF-IR by antisense strategies may be relevant to the clinical treatment of ES patients by reducing the malignant potential of these cells and enhancing the effectiveness of chemotherapy.
|
11896447 |
2002 |
Ewings sarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The IGF-I receptor gene promoter is a molecular target for the Ewing's sarcoma-Wilms' tumor 1 fusion protein.
|
8702614 |
1996 |